Pembrolizumab: all 1,753 studies that test it

Page 14 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.

• Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1Status unknownNCT04999800Phase 2
• A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in AdultsTerminatedNCT04999202Phase 1
• Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell CarcinomaStatus unknownNCT04995016Phase 2
• Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLCStatus unknownNCT04989322Phase 2
• A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced MelanomaActive, not recruitingNCT04971499Phase 1/2
• Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary SyndromeActive, not recruitingNCT04960618Phase 2
• A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck CancerActive, not recruitingNCT04958239Phase 1
• Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')Status unknownNCT04946227Phase 2
• Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx CancersCompletedNCT04943445Phase 2
• Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)Active, not recruitingNCT04938609Phase 2
• NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaActive, not recruitingNCT04930783Phase 1
• Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT04913337Phase 1/2
• REduced Frequency ImmuNE Checkpoint Inhibition in CancersStatus unknownNCT04913025Phase 2
• A Study of Pembrolizumab and Radiation Therapy in People With MesotheliomaActive, not recruitingNCT04897022Phase 1
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)Active, not recruitingNCT04895358Phase 3
• Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic CancerActive, not recruitingNCT04887805Phase 2
• A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 AntibodyStatus unknownNCT04866485Phase 1
• Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )Status unknownNCT04863079Phase 2
• NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell CancerTerminatedNCT04862455Phase 2
• A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid TumorsStatus unknownNCT04859777Phase 1
• Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Phase 3
• First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsActive, not recruitingNCT04858269Phase 2
• A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of ChemoimmunotherapyTerminatedNCT04856176Phase 2
• Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck CancerCompletedNCT04847466Phase 2
• Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsCompletedNCT04840394Phase 1
• Electroporation Potentiated Immunotherapy in CancerActive, not recruitingNCT04835402Phase 2
• A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanomaTerminatedNCT04834973Phase 1/2
• A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and NeckCompletedNCT04830592Phase 1
• Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6TerminatedNCT04830124Phase 2
• RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose RadiotherapyCompletedNCT04827862Phase 2
• Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal CancerActive, not recruitingNCT04825990Phase 2
• Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT04815720Phase 1/2
• Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ AdenocarcinomaStatus unknownNCT04813523Phase 2
• Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
• A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid TumorsTerminatedNCT04799054Phase 1/2
• Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaWithdrawnNCT04795869Phase 2
• Immunotherapy in MSI/dMMR Tumors in Perioperative Setting.Active, not recruitingNCT04795661Phase 2
• Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)CompletedNCT04793815Not applicable
• Tucatinib Together With Pembrolizumab and TrastuzumabTerminatedNCT04789096Phase 2
• Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue SarcomaActive, not recruitingNCT04784247Phase 2
• Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7TerminatedNCT04777851Phase 3
• BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver CancerTerminatedNCT04777708Early Phase 1
• Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Active, not recruitingNCT04753879Phase 2
• HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung CancerStatus unknownNCT04750083Phase 2/3
• Metastatic Solid Cancer Clinical TrialActive, not recruitingNCT04739618Phase 2
• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Active, not recruitingNCT04736706Phase 3
• Pembrolizumab And Lenvatinib In Leptomeningeal MetastasesTerminatedNCT04729348Phase 2
• Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-respondersActive, not recruitingNCT04729322Phase 2
• OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OCActive, not recruitingNCT04713514Phase 2
• A Phase 2 Trial for Patients With Metastatic Solid CancerActive, not recruitingNCT04713371Phase 2
• Pembrolizumab for the Treatment of Cervical Intraepithelial NeoplasiaActive, not recruitingNCT04712851Phase 2
• Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIentsCompletedNCT04710628Phase 2
• Sargramostim (GM-CSF) + PD-1WithdrawnNCT04703426Phase 2
• Cryoablation With Pembrolizumab Or Avelumab In Urothelial CarcinomaCompletedNCT04701918Phase 2
• Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)Active, not recruitingNCT04700124Phase 3
• FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid TumorsStatus unknownNCT04699643Phase 1/2
• The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04699123Phase 2
• Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)Status unknownNCT04699071Phase 2
• Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic MalignancyCompletedNCT04694781Phase 1
• A Study of PY314 in Subjects With Advanced Solid TumorsTerminatedNCT04691375Phase 1
• A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsTerminatedNCT04682431Phase 1
• Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid CancerActive, not recruitingNCT04675710Phase 2
• A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based TherapyActive, not recruitingNCT04666740Phase 2
• CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsActive, not recruitingNCT04660929Phase 1
• Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent MeningiomaActive, not recruitingNCT04659811Phase 2
• GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or PembrolizumabActive, not recruitingNCT04652076Phase 1/2
• Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaActive, not recruitingNCT04643379Phase 2
• Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical CancerStatus unknownNCT04641728Phase 2
• Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04638582Phase 2
• Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)Active, not recruitingNCT04634877Phase 3
• Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) MutationStatus unknownNCT04633902Phase 2
• Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)CompletedNCT04626518Phase 1/2
• Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)CompletedNCT04626479Phase 1/2
• Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active, not recruitingNCT04624204Phase 3
• Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaTerminatedNCT04624113Phase 1
• Lenvatinib and Pembrolizumab in Resectable Mucosal MelanomaStatus unknownNCT04622566Phase 2
• Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic CancersWithdrawnNCT04611139Phase 1
• Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsCompletedNCT04609566Phase 2
• 64Cu-DOTA-pembrolizumab PET for the Study of PD1 ExpressionWithdrawnNCT04605614Phase 1
• Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)Active, not recruitingNCT04592653Phase 1/2
• Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLCStatus unknownNCT04586465Phase 2
• Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of MelanomaCompletedNCT04581382Early Phase 1
• Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian CancerActive, not recruitingNCT04575961Phase 2
• Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)WithdrawnNCT04569461Phase 2
• Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer PatientsWithdrawnNCT04565496Phase 2
• First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid TumorsTerminatedNCT04564417Phase 1
• Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA MutationsActive, not recruitingNCT04548752Phase 2
• PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %Active, not recruitingNCT04547504Phase 3
• Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesActive, not recruitingNCT04541108Early Phase 1
• Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)Active, not recruitingNCT04526691Phase 1
• Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal CancerCompletedNCT04522336Phase 1
• Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid MalignanciesActive, not recruitingNCT04521413Phase 1/2
• Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)Active, not recruitingNCT04520711Phase 1
• A Safety Study of YQ23 in Advanced Solid Tumors PatientsTerminatedNCT04513067Phase 1
• TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain MetastasesWithdrawnNCT04512261Phase 1/2
• TTX-080 HLA-G Antagonist in Subjects With Advanced CancersActive, not recruitingNCT04485013Phase 1
• B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsActive, not recruitingNCT04483778Phase 1
• ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT04471974Phase 2
• BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade TherapyActive, not recruitingNCT04454528Phase 1/2
• Hemopurifier Plus Pembrolizumab in Head and Neck CancerTerminatedNCT04453046Not applicable

← Pembrolizumab overview